US5364622A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Methods for preventing adhesions to organs and parts of organs by application of tissue plasminogen activator and hydroxyethylcellulose hydrogel
Assignee: Boehringer Ingelheim Pharma GmbH and Co KG
•
Filing: 1993-10-13
•
Granted: 1994-11-15
•
Expires: 2013-10-13
Abstract
Abstract A method for the prevention of adhesions to body organs and parts of organs caused by therapeutic intervention by applying a pharmaceutical composition of tissue plasminogen activator and an aqueous hydroxyethylcellulose hydrogel.
Inventors
- 👤 Helmut Franz
- 👤 Thomas Muller
- 👤 Wolfgang Eisert
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 10:59
CPC Classifications
A; A61; A61K; A61K47/00; A61K47/30; A61K47/36; A61K47/38; A61K38/00; A61K38/16; A61K38/43; A61K38/46; A61K38/48; A61K38/49; A61K9/00; A61K9/0012; A61K9/0014
Claims Analysis
Total Claims: 17
Claim 1
Independent Claim
56 words
A method of preventing adhesions to body organs and/or parts of body organs caused by therapeutic intervention comprising applying to a subject a pharmaceutical composition comprising natural or recombinant t-PA, and an aqueous hydroxyethyl cellulose hydrogel wherein said pharmaceutical composition is applied at the site of said intervention in an amount effective to prevent said adhesions.
Claim 2
Independent Claim
56 words
A method of preventing adhesions to body organs and/or parts of body organs caused by therapeutic intervention comprising applying to a subject a pharmaceutical composition comprising natural or recombinant t-PA, and an aqueous hydroxyethyl cellulose hydrogel wherein said pharmaceutical composition is applied at the site of said intervention in an amount effective to prevent said adhesions.
Claim 3
Dependent Claim
22 words
The method of preventing adhesions of claim 1, wherein said body organs and/or said body organ parts are in a body cavity.
Claim 4
Dependent Claim
16 words
The method of preventing adhesions of claim 2, wherein said body cavity is a thoracic cavity.
Claim 5
Dependent Claim
16 words
The method of preventing adhesions of claim 2, wherein said body cavity is an abdominal cavity.
Claim 6
Dependent Claim
14 words
The method of preventing adhesions of claim 1, wherein said therapeutic intervention is invasive.
Claim 7
Dependent Claim
15 words
The method of preventing adhesions of claim 5, wherein said invasive therapeutic intervention is surgery.
Claim 8
Dependent Claim
14 words
The method of preventing adhesions of claim 1, wherein said subject is a mammal.
Claim 9
Dependent Claim
14 words
The method of preventing adhesions of claim 7, wherein said mammal is a human.
Claim 10
Dependent Claim
13 words
The method of preventing adhesions of claim 1, wherein said application is topical.
Claim 11
Dependent Claim
17 words
The method of preventing adhesions of claim 1, wherein said application is by instillation through a tube.
Claim 12
Dependent Claim
17 words
The method of preventing adhesions of claim 1, wherein said pharmaceutical composition further comprises an isotonic solution.
Claim 13
Dependent Claim
17 words
The method of preventing adhesions of claim 1, wherein said pharmaceutical composition further comprises a buffer solution.
Claim 14
Dependent Claim
37 words
The method of preventing adhesions of claim 1, wherein said pharmaceutical composition comprises of 0.1 to 50 mg/ml of natural or recombinant t-PA and said hydrogel comprises 1 to 3% by weight of hydroxyethylcellulose in aqueous solution.
Claim 15
Dependent Claim
22 words
The method of preventing adhesions of claim 13, wherein said pharmaceutical composition comprises 0.3 to 10 mg/ml of natural or recombinant t-PA.
Claim 16
Dependent Claim
35 words
The method of preventing adhesions of claim 13 wherein said pharmaceutical composition comprises 1 to 2 mg/ml of recombinant t-PA and said hydrogel comprises 1 to 3% by weight of hydroxyethylcellulose in a buffer solution.
Claim 17
Dependent Claim
32 words
The method of preventing adhesions of claim 1, wherein said hydrogel comprises hydroxyethylethers of cellulose having an average molecular substitution level of from 1.5 to 3.0 hydroxyethyl groups per unit of anhydroglucose.
References Cited (Backward Citations)
US4346108A
Cited
GB2119804A
Cited
WO1984000111A1
Cited
EP0174835A1
Cited
EP0227400A2
Cited
US4889722A
Cited
US4828836A
Cited
EP0297860B1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1997-11-14 | 1998-05-16 | 1998-11-15 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2001-11-14 | 2002-05-16 | 2002-11-15 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2005-11-14 | 2006-05-16 | 2006-11-15 | $7700.00 | Window Closed / Lapsed |